Friday, 16 October 2026European Markets

IDEX BIOMETRICS Stock Bullish By 10% So Far On Tuesday

Loading stream...

VIANEWS Report - Shares of IDEX Biometrics ASA's (IDEX.OL) have seen an amazing 10.51% jump to Kr0.74, rebounding after two consecutive trading days of losses. On Oslo Bors Benchmark Index -- where this stock is listed -- they showed a slight uptick of 0.06% to reach kr1,237.90 and continue their upward momentum for yet another day in succession.

Norwegian biometric technology company Omnimetric's Performance

Norwegian biometric technology company Omnimetric's last closing price was kr0.67, more than 50% below its peak of approximately one year ago (kr1.37). Omnimetric's services cover designing and developing fingerprint authentication solutions from Norway to Asia-Pacific regions and specialize in contactless financial payment and storage of digital currencies via card-based devices.

The Challenges Ahead for IDEX

However, significant challenges still lie ahead for IDEX. Their trailing 12 months earnings per share (EPS) stands at kr-0.29 - which indicates losses over that time frame - while their return on equity (ROE) sits at negative 135.19%, signaling they may be struggling to use shareholder funds efficiently.

IDEX's Stock Price Over the Last Year

Looking back over the past year, IDEX stock price of kr0.74 stands far lower than its 52-week high of kr1.37 but higher than its low of kr0.65, suggesting considerable price instability within its share price volatility, which registered as negative values over each week, month, and quarter respectively - suggesting an unstable stock with wide price fluctuations.

Looking Forward

Going forward, investors will closely evaluate whether the fundamentals of a company align with its share price growth. Potential shareholders should note the unstable price and negative earnings as these may present higher risk and greater potential returns.

More news about IDEX BIOMETRICS (IDEX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com